Navigation Links
Herborium Announces Continuing Progress In Key Strategic Initiatives
Date:5/4/2012

TEANECK, N.J., May 4, 2012 /PRNewswire/ -- Herborium Group, Inc., (PINKS. HBRM) www.herborium.com, a Botanical Therapeutics® company, reports today continuing progress with its key strategic initiatives.

The company is progressing through the negotiating phase with China Health Resource Inc. regarding a potential acquisition. Both, Herborium Group and China Resource continue to work diligently towards a successful transaction.      

Herborium's partnership with KAMASUTRA (USA), LLC  to commercialize their unique vodka product containing Herborium's proprietary herbal formula  derived from the Company's sexual health formulations, has moved into the introductory marketing phase with the digital marketing plan to be initiated in June 2012.  Market share for vodka in the US is $4.8 Billion in annual sales with both on premise and home consumption on the rise.  KAMASUTRA (USA) LLC is the US partner of the German Bismarck Premium Brands GmbH  www.bismarck.de  and http://www.bismarck.de/kamasutra/englisch/kamasutra_ginseng_vodka.html.

The market for pharmaceutical sexual health products is over $3.2 billion worldwide. The market for natural sexual health products is estimated to be over $1.5 billion, and growing.

Dr. Agnes P. Olszewski, CEO of Herborium, recently completed the National Publicity Summit in New York City (April 25-29, 2012). The Company is looking forward to multiple media exposure opportunities resulting from this Summit  that shall greatly elevate  Herborium's  public awareness.

About Herborium Group, Inc.

Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company uses clinical validation to establish and maintain a differential advantage. The company markets its products in the US and Europe. For more information, please visit www.herborium.com and www.acnease.com.

One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.

For more information please inquire: Investorsrelations@herborium.com


'/>"/>
SOURCE Herborium Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Herborium Group Shareholders Update
2. Bacterin Announces First Quarter 2012 Revenue of $7.8 Million, Up 29% Year-over-Year, on Gross Margins of 76%, and 34% Reduction in Operating Loss
3. DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
4. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
5. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
6. Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India
7. Angioslide Announces FDA 510(K) Clearance of PROTEUS(TM) Below The Knee Device
8. Hill-Rom Announces Third Quarter 2012 Dividend
9. Trovagene Announces Plans to Develop Proprietary Test for High Risk HPV Carrier Screening from Urine
10. Medical Guardian Announces Social Media Partnership with Senior Citizen Charity
11. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
(Date:6/24/2016)... ... 2016 , ... National recruitment firm Slone Partners is pleased to ... genomics experience, as Vice President of North American Capital Sales at HTG Molecular ... the sales team in the commercialization of the HTG EdgeSeq system and associated reagents ...
Breaking Medicine News(10 mins):